Lantern Pharma Current Financial Leverage
LTRN Stock | USD 5.77 0.05 0.87% |
Lantern Pharma holds a debt-to-equity ratio of 0.002. As of the 24th of April 2024, Net Debt To EBITDA is likely to grow to 1.58, while Net Debt is likely to drop (22.8 M). Lantern Pharma's financial risk is the risk to Lantern Pharma stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Lantern Pharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Lantern Pharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Lantern Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Lantern Pharma's stakeholders.
For most companies, including Lantern Pharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Lantern Pharma the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 1.6805 | Book Value 3.816 | Return On Assets (0.22) | Return On Equity (0.33) |
Given that Lantern Pharma's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Lantern Pharma is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Lantern Pharma to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Lantern Pharma is said to be less leveraged. If creditors hold a majority of Lantern Pharma's assets, the Company is said to be highly leveraged.
As of the 24th of April 2024, Net Debt To EBITDA is likely to grow to 1.58, while Net Debt is likely to drop (22.8 M). Lantern |
Lantern Pharma Financial Leverage Rating
Lantern Pharma bond ratings play a critical role in determining how much Lantern Pharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Lantern Pharma's borrowing costs.Piotroski F Score | 3 Frail |
Beneish M Score | -5.06 Unlikely Manipulator |
Lantern Pharma Debt to Cash Allocation
As Lantern Pharma follows its natural business cycle, the capital allocation decisions will not magically go away. Lantern Pharma's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 234.47 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Lantern Pharma has a current ratio of 12.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Lantern Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Lantern Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lantern Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lantern to invest in growth at high rates of return. When we think about Lantern Pharma's use of debt, we should always consider it together with cash and equity.Lantern Pharma Total Assets Over Time
Lantern Pharma Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Lantern Pharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Lantern Pharma, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a a Lantern Pharma debt ratio should be compared their industry average or other competing firms.Lantern Net Debt
Understaning Lantern Pharma Use of Financial Leverage
Lantern Pharma financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Lantern Pharma's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Lantern Pharma assets, the company is considered highly leveraged. Understanding the composition and structure of overall Lantern Pharma debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to Lantern Pharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Lantern Pharma's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
Last Reported | Projected for Next Year | ||
Net Debt | -21.7 M | -22.8 M | |
Short and Long Term Debt Total | 234.5 K | 165.2 K | |
Long Term Debt | 97.7 K | 86.8 K | |
Short Term Debt | 173 K | 138.6 K | |
Net Debt To EBITDA | 1.23 | 1.58 | |
Debt To Equity | 0.01 | 0.01 | |
Interest Debt Per Share | 0.02 | 0.02 | |
Debt To Assets | 0.01 | 0.01 | |
Long Term Debt To Capitalization | 0 | 0 | |
Total Debt To Capitalization | 0.01 | 0.01 | |
Debt Equity Ratio | 0.01 | 0.01 | |
Debt Ratio | 0.01 | 0.01 | |
Cash Flow To Debt Ratio | (61.19) | (64.25) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lantern Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lantern Pharma's short interest history, or implied volatility extrapolated from Lantern Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Lantern Pharma Fundamentals Over Time. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Lantern Stock analysis
When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.